KR102120505B1 - 통증 치료용 아자인다졸 또는 디아자인다졸 타입의 유도체 - Google Patents

통증 치료용 아자인다졸 또는 디아자인다졸 타입의 유도체 Download PDF

Info

Publication number
KR102120505B1
KR102120505B1 KR1020157004735A KR20157004735A KR102120505B1 KR 102120505 B1 KR102120505 B1 KR 102120505B1 KR 1020157004735 A KR1020157004735 A KR 1020157004735A KR 20157004735 A KR20157004735 A KR 20157004735A KR 102120505 B1 KR102120505 B1 KR 102120505B1
Authority
KR
South Korea
Prior art keywords
charom
arom
pain
mmol
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157004735A
Other languages
English (en)
Korean (ko)
Other versions
KR20150038295A (ko
Inventor
삐에르 쏘꼴로프
프레데리끄 까꾸
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20150038295A publication Critical patent/KR20150038295A/ko
Application granted granted Critical
Publication of KR102120505B1 publication Critical patent/KR102120505B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020157004735A 2012-07-27 2013-07-29 통증 치료용 아자인다졸 또는 디아자인다졸 타입의 유도체 Expired - Fee Related KR102120505B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305922.2 2012-07-27
EP12305922.2A EP2689778A1 (en) 2012-07-27 2012-07-27 Derivatives of azaindoles or diazaindoles for treating pain
PCT/EP2013/065907 WO2014016433A1 (en) 2012-07-27 2013-07-29 Derivatives of azaindazole or diazaindazole type for treating pain

Publications (2)

Publication Number Publication Date
KR20150038295A KR20150038295A (ko) 2015-04-08
KR102120505B1 true KR102120505B1 (ko) 2020-06-08

Family

ID=48948392

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157004735A Expired - Fee Related KR102120505B1 (ko) 2012-07-27 2013-07-29 통증 치료용 아자인다졸 또는 디아자인다졸 타입의 유도체

Country Status (28)

Country Link
US (1) US9381195B2 (https=)
EP (2) EP2689778A1 (https=)
JP (2) JP6456823B2 (https=)
KR (1) KR102120505B1 (https=)
CN (1) CN104684554B (https=)
AU (1) AU2013294920B2 (https=)
BR (1) BR112015001502B1 (https=)
CA (1) CA2879595C (https=)
CY (1) CY1118478T1 (https=)
DK (1) DK2877177T3 (https=)
ES (1) ES2612349T3 (https=)
HR (1) HRP20170104T1 (https=)
HU (1) HUE032919T2 (https=)
IL (1) IL236917A (https=)
LT (1) LT2877177T (https=)
MA (1) MA37866B1 (https=)
MX (1) MX363605B (https=)
MY (1) MY183398A (https=)
NZ (1) NZ705253A (https=)
PL (1) PL2877177T3 (https=)
PT (1) PT2877177T (https=)
RS (1) RS55646B1 (https=)
RU (1) RU2640046C2 (https=)
SI (1) SI2877177T1 (https=)
TN (1) TN2015000034A1 (https=)
UA (1) UA116107C2 (https=)
WO (1) WO2014016433A1 (https=)
ZA (1) ZA201501209B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
KR20170095814A (ko) 2014-10-06 2017-08-23 플랫틀리 디스커버리 랩, 엘엘씨 트라이아졸로피리딘 화합물 및 낭성 섬유증의 치료 방법
CN113354649B (zh) 2014-11-16 2024-12-10 阵列生物制药公司 一种新的晶型
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3458456B1 (en) 2016-05-18 2020-11-25 Loxo Oncology Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (ja) * 2016-10-31 2018-05-03 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する縮合複素環および縮合炭素環誘導体
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US12583852B2 (en) 2018-05-02 2026-03-24 Jw Pharmaceutical Corporation Heterocycle derivative
KR102129114B1 (ko) 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
AU2024275348A1 (en) * 2023-05-24 2025-12-11 Changchun Genescience Pharmaceutical Co., Ltd. Fgfr2/3 selective inhibitor, pharmaceutical composition and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041525A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
WO2007023110A2 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
KR101923751B1 (ko) * 2011-01-27 2018-11-29 피에르 파브르 메디카먼트 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
EP1292586B1 (en) 2000-06-22 2004-08-04 Pfizer Limited Process for the preparation of pyrazolopyrimidinones
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
MX2009006401A (es) * 2006-12-20 2009-06-23 Nerviano Medical Sciences Srl Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
PT2176231T (pt) 2007-07-20 2016-12-09 Nerviano Medical Sciences Srl Derivados de indazol substituídos activos como inibidores de quinases
US8354399B2 (en) * 2008-12-18 2013-01-15 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041525A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
WO2007023110A2 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
KR101923751B1 (ko) * 2011-01-27 2018-11-29 피에르 파브르 메디카먼트 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체

Also Published As

Publication number Publication date
KR20150038295A (ko) 2015-04-08
MY183398A (en) 2021-02-18
MA37866B1 (fr) 2016-12-30
SI2877177T1 (sl) 2017-02-28
CN104684554A (zh) 2015-06-03
HK1207302A1 (en) 2016-01-29
EP2689778A1 (en) 2014-01-29
EP2877177B1 (en) 2016-10-26
JP6456823B2 (ja) 2019-01-23
PL2877177T3 (pl) 2017-04-28
UA116107C2 (uk) 2018-02-12
BR112015001502B1 (pt) 2023-03-07
RU2015106434A (ru) 2016-09-20
JP2015522650A (ja) 2015-08-06
TN2015000034A1 (en) 2016-06-29
CY1118478T1 (el) 2017-07-12
CA2879595A1 (en) 2014-01-30
US20150190394A1 (en) 2015-07-09
IL236917A (en) 2016-11-30
RS55646B1 (sr) 2017-06-30
JP2019031542A (ja) 2019-02-28
AU2013294920B2 (en) 2017-08-24
BR112015001502A2 (pt) 2017-07-04
ZA201501209B (en) 2016-03-30
US9381195B2 (en) 2016-07-05
CN104684554B (zh) 2017-05-10
HUE032919T2 (hu) 2017-11-28
JP6732855B2 (ja) 2020-07-29
MA37866A1 (fr) 2016-05-31
HRP20170104T1 (hr) 2017-03-24
ES2612349T3 (es) 2017-05-16
PT2877177T (pt) 2017-02-06
MX2015001009A (es) 2015-06-04
WO2014016433A1 (en) 2014-01-30
LT2877177T (lt) 2017-01-25
RU2640046C2 (ru) 2017-12-26
DK2877177T3 (en) 2017-02-06
AU2013294920A1 (en) 2015-03-12
EP2877177A1 (en) 2015-06-03
MX363605B (es) 2019-03-26
NZ705253A (en) 2017-05-26
CA2879595C (en) 2020-07-28

Similar Documents

Publication Publication Date Title
KR102120505B1 (ko) 통증 치료용 아자인다졸 또는 디아자인다졸 타입의 유도체
KR101923751B1 (ko) 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체
EP2877176B1 (en) Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
HK1207302B (en) Derivatives of azaindazole or diazaindazole type for treating pain
OA17324A (en) Derivatives of azaindazole or diazaindazole type for treating pain.
HK1186737B (en) Derivatives of azaindazole or diazaindazole type as medicament
OA16493A (en) Derivatives of azaindazole or diazaindazole type as medicament.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250603

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250603

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250603